23:04 , Apr 23, 2019 |  BC Innovations  |  Translation in Brief

J&J and Boston University identify classifications to catch lung cancer

J&J and Boston University identified a subtype of precancerous lesions with genomic alterations and immune cell deficiencies that could be used to diagnose and stratify patients at the earliest stages of lung cancer. The findings,...
22:58 , Apr 4, 2019 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: March 2019

New Therapeutic Targets and Biomarkers: March 2019 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during March. Therapeutic targets are defined as any protein, gene or other molecule...
21:16 , Mar 5, 2019 |  BC Innovations  |  Distillery Therapeutics

MC1R, ZDHHC13 and LYPLA2 as new targets for melanoma

DISEASE CATEGORY: Cancer INDICATION: Melanoma Mouse studies suggest activating MC1R by expressing ZDHHC13 or inhibiting LYPLA2 could help treat melanoma. In a mouse model of melanoma, transgenic expression of human ZDHHC13, which palmitoylates MC1R to...
21:18 , Feb 11, 2019 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Melanoma In vitro , cell culture and mouse studies identified a quinazolinamine-based STK19 inhibitor that could help treat NRAS-mutant melanoma. In vitro screening of a small molecule library and optimization of the top hit...
18:38 , Feb 5, 2019 |  BC Extra  |  Company News

Management tracks: Amazon-Berkshire Hathaway-JPM venture hires Kutan as CTO

Serkan Kutan started in January as the CTO of the healthcare venture from J.P. Morgan (NYSE:JPM), Berkshire Hathaway Inc. (NYSE:BRK-A; NYSE:BRK-B) and Amazon.com Inc. (NASDAQ:AMZN). He was CTO of Zocdoc Inc. (New York, N.Y.), a...
01:07 , Jan 8, 2019 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Hepatitis C virus (HCV) Cell culture studies identified two aryl pyrimidinone-based compounds that could help treat HCV. Chemical synthesis and testing in a human liver cell-based infection assay of analogs of the natural product...
20:44 , Jan 3, 2019 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: December 2018

New Therapeutic Targets and Biomarkers: December 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during December. Therapeutic targets are defined as any protein, gene or other molecule...
23:59 , Dec 11, 2018 |  BC Innovations  |  Distillery Techniques

Disease models

TECHNOLOGY: Animal models Mice with activated PRSS1 could be used to screen therapies to treat acute and chronic pancreatitis. Mice engineered to express a mutant, activated mouse homolog of PRSS1 recapitulated the pancreatic edema, neutrophil...
17:53 , Nov 9, 2018 |  BC Week In Review  |  Company News

J&J adds to lung cancer arsenal with Yuhan deal

Janssen Pharmaceuticals Inc. licensed non-small cell lung cancer (NSCLC) compound lazertinib from Yuhan Corp. (KSE:000100) for $50 million up front and up to $1.2 billion in development and commercial milestones, giving Johnson & Johnson (NYSE:JNJ)...
00:15 , Nov 6, 2018 |  BC Extra  |  Company News

J&J adds to lung cancer arsenal with Yuhan deal

Janssen Pharmaceuticals Inc. licensed non-small cell lung cancer (NSCLC) compound lazertinib from Yuhan Corp. (KSE:000100) for $50 million up front and up to $1.2 billion in development and commercial milestones, giving Johnson & Johnson (NYSE:JNJ)...